| HOME >> BIOLOGY >> TECHNOLOGY |
$73,502$69,986$113,686$114,531Add back:Loss on repurchase of convertible debt, net of estimated taxes
-498-498Amortization of debt discount on Series 2012 Notes and May 2015 Notes, net of estimated taxes
1,6423373,238337Non-GAAP net income
75,14470,821116,924115,366Add back interest expense for convertible notes, net of estimated taxes
61,275332,549Non-GAAP income used to compute non-GAAP net income per diluted share
$75,150$72,096$116,957$117,915Shares used to compute non-GAAP net income per diluted share
142,213186,060142,890186,055Non-GAAP net income per diluted share
$
.53$
.39$
.82$
.63 PDL BIOPHARMA, INC. CONDENSED CONSOLIDATED BALANCE SHEET DATA(Unaudited)(In thousands) June 30, 2012December 31, 2011Cash, cash equivalents and investments$
229,333$
227,946Total assets$
259,829$
269,471Non-recourse notes payable$
22,738$
93,370Convertible notes payable$
304,767$
316,615Total stockholders' deficit$
(161,114)$
(204,273) PDL BIOPHARMA, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW DATA (Unaudited)(In thousands) Six Months Ended June 30,20122011Net income$113,686$114,531Adjustments to reconcile net income to net cash provided by operating activities12,77924,941Changes in assets and liabilities(3,672)(51,549)Net cash provided by operating activities$122,793$ 87,923
| SOURCE PDL BioPharma, Inc. Copyright©2012 PR Newswire. All rights reserved |